Evotec AG is a drug discovery and development company. The Company operates through two segments. The EVT Execute segment provides standalone drug discover services on a typical fee-for-service basis or integrated drug discovery collaborations on partners' target through a range of commercial structures, including research fees, milestones and/or royalties. The EVT Innovate segment develops drug discovery programs and assets, both internally or through academic collaborations. The Company seeks to partner these into collaborations in return for upfront payments, ongoing research payments. It consists of all partnerships derived from its internally developed assets and platforms and its participations in certain companies. It includes clinical initiations and progress of clinical pipeline within partnerships; expansion of academic BRIDGE network; research and development (R&D) progress with CureX/Target X initiatives, and focuses on induced pluripotent stem cells (iPSC) platform.

Pharmaceutical

Evotec

Craig Johnstone

Laetitia Rouxel

Cord Dohrmann

Hans-Ulrich Wolf

The Business Development and Strategy Team at Evotec is responsible for identifying, negotiating, and managing strategic partnerships that enhance the company's drug discovery and development initiatives. This team engages with potential collaborators across academia and industry to establish agreements that drive research funding, share innovation, and accelerate the advancement of therapeutic programs. By leveraging their extensive networks and expertise, they aim to expand Evotec's global reach and optimize the integration of innovative solutions into the company’s portfolio.

Business Development and Strategy Team

About

Team members

Other teams at Evotec

Scientific Research Team

Leadership Team